Business Context and Reporting Period
This Form 6-K, dated January 12, 2026, reports on Legend Biotech Corporation's recent business updates presented at the 44th Annual J.P. Morgan Healthcare Conference. The company is a global leader in cell therapy, focusing on its flagship product CARVYKTI and its broader pipeline of oncology and immunology candidates.
Key Financial Metrics
- Liquidity: Cash, cash equivalents, and time deposits totaled approximately $1.0 billion as of September 30, 2025.
- Profitability Outlook: The company anticipates the CARVYKTI franchise will achieve profitability in fiscal year 2025 and expects company-wide operating profit in 2026.
- Financial Runway: Management believes current liquidity provides a runway extending beyond 2026.
- Revenue and Margins: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
- Debt: The filing text does not provide specific debt figures.
Material Changes and Operational Progress
- Commercial Expansion: CARVYKTI has treated over 10,000 clinical and commercial patients. Global availability expanded in 2025 to more than 279 sites across 14 markets.
- Manufacturing Capacity: The Raritan facility expansion is complete, now the largest cell therapy manufacturing facility in the U.S. with capacity to support up to 10,000 patients annually.
- Regulatory and Label Updates: Received FDA and European Commission approval to include overall survival benefits in the CARVYKTI label, supported by Phase 3 CARTITUDE-4 data.
- Clinical Milestones: Completed enrollment for the Phase 3 CARTITUDE-6 trial in newly-diagnosed multiple myeloma patients in August 2025. Presented data showing a median progression-free survival of 50.4 months for triple-class-exposed patients.
- Pipeline Advancement: Opened a new 31,000-square-foot R&D facility in Philadelphia. Dosed the first patient with an in vivo dual CD20/CD19-targeted cell therapy, with first-in-human data expected in the second half of 2026.
Guidance, Outlook, and Risks
- Strategic Priorities for 2026: Focus on maximizing CARVYKTI market leadership, advancing cell therapy innovation (including allogeneic CAR-T candidate LUCAR-G39D), and driving profitability.
- Future Filings: Targeting multiple Investigational New Drug (IND) filings for oncology and autoimmune indications starting in the second half of 2026.
- Risks and Contingencies: Forward-looking statements are subject to risks including clinical trial uncertainties, regulatory delays, third-party partner failures, intellectual property litigation, and pricing pressures. Actual results may differ materially from expectations.
Key Facts for Investor Verification
- Verification of the $1.0 billion cash position as of September 30, 2025, in the most recent audited financial statements.
- Confirmation of the timeline for achieving company-wide operating profit in 2026.
- Monitoring of the Phase 3 CARTITUDE-6 trial results and the timing of the first-in-human data for the in vivo platform (expected H2 2026).
- Assessment of the impact of the updated CARVYKTI label on market adoption and reimbursement.
- Review of the status of the Raritan facility's operational capacity to meet the 10,000 patient annual target.